Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention | Zendy

Philipp Steininger | Zendy; Tobias Bobinger | Zendy; W. Dietrich | Zendy; De-Hyung Lee | Zendy; Michael Knott | Zendy; Christian Bogdan | Zendy; Klaus Korn | Zendy; Roland Lang | Zendy

Open Access

Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention

Author(s) -

Philipp Steininger,

Tobias Bobinger,

W. Dietrich,

De-Hyung Lee,

Michael Knott,

Christian Bogdan,

Klaus Korn,

Roland Lang

Publication year - 2017

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofx204

Subject(s) - medicine , rituximab , tick borne encephalitis , encephalitis , vaccination , immunology , virology , virus , pediatrics , antibody

Rituximab (RTX) has become a standard therapy for certain B cell malignancies and autoimmune diseases. We report 2 RTX-treated patients who developed severe tick-borne encephalitis virus (TBEV) infection. The inability to generate new antibody responses renders RTX-treated patients susceptible to TBEV, impedes laboratory diagnosis, and necessitates preventive vaccination in endemic areas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research